Latest & greatest articles for benazepril

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on benazepril or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on benazepril and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for benazepril

1. Comparison Between Losartan and Benazepril in Diabetic Hypertensive Patients Not Controlled by Amlodipine

Comparison Between Losartan and Benazepril in Diabetic Hypertensive Patients Not Controlled by Amlodipine Comparison Between Losartan and Benazepril in Diabetic Hypertensive Patients Not Controlled by Amlodipine - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100 (...) ). Please remove one or more studies before adding more. Comparison Between Losartan and Benazepril in Diabetic Hypertensive Patients Not Controlled by Amlodipine (CONTROL) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT01603940 Recruitment Status : Completed First Posted : May 23, 2012 Results First

2012 Clinical Trials

2. Effect of benazepril and pimobendan on serum angiotensin-converting enzyme activity in dogs. (Abstract)

Effect of benazepril and pimobendan on serum angiotensin-converting enzyme activity in dogs. To support their combined use, the objective of the study was to evaluate the effects of benazepril and pimobendan on serum angiotensin-converting enzyme (ACE) activity in dogs. A total of 48 healthy beagle dogs were randomized into four groups (n = 12 per group) in a parallel-group design study: A (control, placebo twice daily (BID)); B (0.5-1.0 mg/kg benazepril once daily (SID) in the morning, placebo (...) in the evening); C (0.25-0.5 mg/kg benazepril BID); D (0.25-0.5 mg/kg benazepril and 0.125-0.25 mg/kg pimobendan, both BID). The test items were administered orally for 15 days. Serum ACE activity was measured on days 1 and 15. Groups B, C and D had significantly lower average serum ACE activity compared to baseline and to the control group, on both days 1 and 15. There were no significant differences in average ACE activity between groups B, C and D. Noninferiority of group C to B was demonstrated

2018 Journal of veterinary pharmacology and therapeutics Controlled trial quality: uncertain

3. Comparison of Benazepril Plus Amlodipine or Hydrochlorothiazide in High-Risk Patients With Hypertension and Coronary Artery Disease. (Abstract)

Comparison of Benazepril Plus Amlodipine or Hydrochlorothiazide in High-Risk Patients With Hypertension and Coronary Artery Disease. Combination therapy with benazepril 40 mg and amlodipine 10 mg (B+A) has been shown to be more effective than benazepril 40 mg and hydrochlorothiazide (HCTZ) 25 mg (B+H) in reducing cardiovascular (CV) events in high-risk patients with stage 2 hypertension with similar blood pressure reductions. In the present post hoc analysis, we evaluated whether B+A is more

2013 American Journal of Cardiology Controlled trial quality: uncertain

4. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. (Full text)

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. The optimal combination drug therapy for hypertension is not established, although current U.S. guidelines recommend inclusion of a diuretic. We hypothesized that treatment with the combination of an angiotensin-converting-enzyme (ACE) inhibitor and a dihydropyridine calcium-channel blocker would be more effective in reducing the rate of cardiovascular events than treatment with an ACE inhibitor plus (...) a thiazide diuretic.In a randomized, double-blind trial, we assigned 11,506 patients with hypertension who were at high risk for cardiovascular events to receive treatment with either benazepril plus amlodipine or benazepril plus hydrochlorothiazide. The primary end point was the composite of death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, hospitalization for angina, resuscitation after sudden cardiac arrest, and coronary revascularization.The baseline characteristics

2008 NEJM Controlled trial quality: predicted high PubMed abstract

5. A multicenter study of the safety and efficacy of benazepril hydrochloride, a long-acting angiotensin-converting enzyme inhibitor, in patients with chronic congestive heart failure. (Abstract)

A multicenter study of the safety and efficacy of benazepril hydrochloride, a long-acting angiotensin-converting enzyme inhibitor, in patients with chronic congestive heart failure. Benazepril hydrochloride is a nonsulfhydryl, long-acting angiotensin-converting enzyme inhibitor that is orally effective. This study was designed to determine the acute hemodynamic effects of this agent in patients with chronic congestive heart failure. Twenty-six patients with New York Heart Association class III (...) or IV congestive heart failure and left ventricular ejection fractions less than 35%, cardiac indexes less than 2.1 L/min/m2, and pulmonary artery wedge pressures greater than 12 mm Hg were given 2 or 5 mg benazepril hydrochloride. All does produced significant (p less than 0.05) increases in cardiac output (26.7% to 31.6% above control) and heart rate (5.4% to 11.2% above control) and decreases in systemic (27.1% to 32.0% below control) and pulmonary (34.8% to 55.5% below control) vascular

1989 Clinical pharmacology and therapeutics

6. Effect of benazepril and robenacoxib and their combination on glomerular filtration rate in dogs. (Full text)

Effect of benazepril and robenacoxib and their combination on glomerular filtration rate in dogs. Combined use of angiotensin-converting enzyme inhibitors and nonsteroidal anti-inflammatory drugs may induce acute kidney injury, especially when combined with diuretics. The objective of this investigation was to evaluate the effect of benazepril, robenacoxib and their combination in healthy dogs. In each of two studies (studies 1 and 2), 32 beagle dogs were randomized into one of four groups (...) in a parallel-group design. Groups received once-daily oral treatment for 7 days with placebo, benazepril, robenacoxib or benazepril plus robenacoxib. In study 2, all dogs received additionally 2 mg/kg furosemide orally twice daily. The primary endpoint was the glomerular filtration rate (GFR) estimated from the plasma clearance of iohexol. Secondary endpoints included standard clinical monitoring and, in study 2, plasma renin activity, urine volume, specific gravity and aldosterone concentration and water

2016 Journal of veterinary pharmacology and therapeutics PubMed abstract

7. Comparison of the effects of long-term pimobendan and benazepril administration in normal cats. (Full text)

Comparison of the effects of long-term pimobendan and benazepril administration in normal cats. Pimobendan (PIMO) can cause adverse effects, such as mitral valve degeneration, in dogs; however, it is unclear whether these effects occur in cats. Therefore, we aimed to determine whether PIMO or benazepril produces adverse cardiac effects in healthy cats. This was a blinded, randomized, prospective parallel study. Twelve cats were randomly divided into two groups of six cats, namely (...) , an angiotensin-converting-enzyme inhibitor group that received benazepril and a PIMO group. Cats were administered their respective treatments for 506 days, and we evaluated cardiac parameters, blood biochemistry and glomerular filtration rates during that time. At the end of the trial, the cats were euthanized, and histopathological examinations were performed by a pathologist who was blinded to the treatment groups. No significant changes were observed in any of the parameters measured in either

2016 The Journal of veterinary medical science / the Japanese Society of Veterinary Science Controlled trial quality: uncertain PubMed abstract

8. Efficacy and safety of the treatment: combination of benazepril/lercanidipine vs. benazepril alone in patients with mild-to-moderate hypertension. (Abstract)

Efficacy and safety of the treatment: combination of benazepril/lercanidipine vs. benazepril alone in patients with mild-to-moderate hypertension. Combination therapy is an effective method to reduce the blood pressure (BP) for patients with hypertension. This study was performed to evaluate the efficacy and safety of benazepril/lercanidipine compared with benazepril alone in patients with mild-to-moderate hypertension.One hundred and eighty-one patients with mild-to-moderate primary (...) hypertension were assigned in this randomized, single-blind, parallel-group study and were randomly divided into group A (benazepril 10 mg/lercanidipine 10 mg) and group B (benazepril 10 mg) for 8 weeks. At 4 weeks, the dosage of Benazepril was titrated up to 20 mg if the diastolic blood pressure (DBP) remained ≥ 90 mmHg. BP control and side effects were evaluated at the end of 1, 4 and 8 weeks.The baseline characteristics of the two groups were similar. The BP in both groups decreased from the baseline (P

2014 Chinese medical journal Controlled trial quality: uncertain

9. Preliminary investigation of orally administered benazepril in horses with left-sided valvular regurgitation. (Abstract)

Preliminary investigation of orally administered benazepril in horses with left-sided valvular regurgitation. Despite the paucity of data available, orally administered angiotensin-converting enzyme (ACE) inhibitors are empirically used in horses with valvular regurgitation.Evaluate the echocardiographic and hormonal changes in response to oral benazepril in horses with left-sided valvular regurgitation.Prospective, randomised double-blind, placebo-controlled trial.Horses with mitral valve (MR (...) ) and/or aortic valve regurgitation (AR) received oral benazepril (n = 6) at a dosage of 1 mg/kg q 12 h or a placebo (n = 5) for 28 days. Echocardiography was performed before drug administration and after 28 days of treatment. Plasma renin activity, serum ACE activity, angiotensin II concentration, aldosterone concentration and biochemical variables were measured before drug administration and after 7 and 28 days of treatment.Relative to baseline, horses treated with benazepril had statistically significant

2018 Equine veterinary journal Controlled trial quality: predicted high

10. Clinical and economic effects of replacing enalapril with benazepril in hypertensive patients. (Full text)

Clinical and economic effects of replacing enalapril with benazepril in hypertensive patients. 8879328 1997 02 03 2019 02 21 1079-2082 53 18 1996 Sep 15 American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists Am J Health Syst Pharm Clinical and economic effects of replacing enalapril with benazepril in hypertensive patients. 2191-3 Briscoe T A TA Pharmacy Department, Grady Health System, Atlanta, GA 30335-3801, USA. Dearing C J (...) CJ eng Clinical Trial Journal Article Randomized Controlled Trial England Am J Health Syst Pharm 9503023 1079-2082 0 Angiotensin-Converting Enzyme Inhibitors 0 Antihypertensive Agents 0 Benzazepines 69PN84IO1A Enalapril UDM7Q7QWP8 benazepril IM Angiotensin-Converting Enzyme Inhibitors economics therapeutic use Antihypertensive Agents economics therapeutic use Benzazepines economics therapeutic use Blood Pressure drug effects Drug Costs Drug Utilization Review economics Enalapril economics

1997 American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists Controlled trial quality: uncertain PubMed abstract

11. The effect of renal diet in association with enalapril or benazepril on proteinuria in dogs with proteinuric chronic kidney disease. (Full text)

The effect of renal diet in association with enalapril or benazepril on proteinuria in dogs with proteinuric chronic kidney disease. Treating proteinuria in dogs reduces the progression of chronic kidney disease (CKD); renal diets and angiotensin-converting enzyme (ACE)-inhibitors are cornerstones of treatment. Whether different ACE-inhibitors have distinct kidney protective effects is unknown; it is therefore hypothesized that renal diets and enalapril or benazepril have different beneficial (...) effects in proteinuric CKD dogs. Forty-four dogs with proteinuric CKD (IRIS stages 1-4) were enrolled in the study and were fed renal diet for 30 days. Thereafter, they were randomly assigned to one of 2 groups. Dogs in group A (n=22) received enalapril (0.5 mg/kg, q12h) and in group B (n=22) benazepril (0.5 mg/kg, q24h); in both groups, dogs were fed the same renal diet. After randomization, dogs were monitored for 120 days. Body weight and body condition score (BCS), serum concentrations

2016 Open veterinary journal Controlled trial quality: uncertain PubMed abstract

12. [Is the combination of benazepril and amlodipine more effective in hypertension than the combination of benazepril and hydrochlorothiazide? Results of the ACCOMPLISH trial]. (Abstract)

[Is the combination of benazepril and amlodipine more effective in hypertension than the combination of benazepril and hydrochlorothiazide? Results of the ACCOMPLISH trial]. 19254225 2009 06 09 2017 03 10 0022-9040 49 2 2009 Kardiologiia Kardiologiia [Is the combination of benazepril and amlodipine more effective in hypertension than the combination of benazepril and hydrochlorothiazide? Results of the ACCOMPLISH trial]. 81-2 Preobrazhenskiĭ D V DV rus Comparative Study Journal Article (...) Multicenter Study Randomized Controlled Trial Russia (Federation) Kardiologiia 0376351 0022-9040 0 Angiotensin-Converting Enzyme Inhibitors 0 Benzazepines 0 Calcium Channel Blockers 0 Diuretics 0J48LPH2TH Hydrochlorothiazide 1J444QC288 Amlodipine UDM7Q7QWP8 benazepril IM Aged Amlodipine therapeutic use Angiotensin-Converting Enzyme Inhibitors therapeutic use Benzazepines therapeutic use Blood Pressure drug effects physiology Calcium Channel Blockers therapeutic use Diuretics therapeutic use Drug Therapy

2009 Kardiologiia Controlled trial quality: uncertain

13. Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial. (Abstract)

Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial. To evaluate whether angiotensin-converting enzyme (ACE) inhibitor and angiotensin II receptor blocker (ARB) combination therapy is more nephroprotective than ACE inhibitor or ARB monotherapy in people with type 2 diabetes and overt nephropathy.In this prospective, randomized, open, blind-endpoint phase III trial sponsored by the Italian Drug Agency, 103 (...) consenting patients with type 2 diabetes, aged >40 years, with serum creatinine levels 159 to 309 μmol/L, spot morning urinary albumin-creatinine ratio > 1000 mg/g (or > 500 mg/g in those on ACE inhibitor or ARB therapy at inclusion) were stratified by centre and randomized to 4.5-year treatment with valsartan 320 mg/d (n = 36), benazepril 20 mg/d (n = 34) or halved doses of both medications (n = 33). The primary endpoint was end-stage renal disease (ESRD). Modified intention-to-treat analyses were

2019 obesity & metabolism Controlled trial quality: predicted high

14. Safety of a benazepril and pimobendan combination tablet in adult healthy dogs. (Abstract)

Safety of a benazepril and pimobendan combination tablet in adult healthy dogs. The objective of the study was to investigate the safety of a combination tablet of benazepril and pimobendan, Fortekor PLUS® , in a randomized, blinded, parallel-group design study in healthy adult beagle dogs. The test article, Fortekor PLUS® tablets, was administered orally twice daily for 6 months at one, two, and four times the highest recommended dosage of 0.5 mg/kg benazepril hydrochloride/0.25 mg/kg

2018 Journal of veterinary pharmacology and therapeutics Controlled trial quality: uncertain

15. Efficacy and tolerability of a switch to fixed-dose combination therapy with amlodipine besylate/benazepril hydrochloride after monotherapy with amlodipine besylate: Data from the African-American subpopulation of a practice-based, open-label study (the L (Full text)

Efficacy and tolerability of a switch to fixed-dose combination therapy with amlodipine besylate/benazepril hydrochloride after monotherapy with amlodipine besylate: Data from the African-American subpopulation of a practice-based, open-label study (the L The LOGIC (LOtrel: Gauging Improved Control) study assessed the efficacy and tolerability of switching from amlodipine besylate monotherapy to fixed-dose combination therapy with amlodipine besylate/benazepril hydrochloride (HCI) in patients (...) who were experiencing uncontrolled blood pressure (BP) or edema with monotherapy.This article reports the efficacy and tolerability of amlodipine besylate/benazepril HCI combination therapy in the predefined African-American population of the LOGIC study.This multicenter (1518 centers across the United States), practice-based, open-label, clinical trial enrolled patients with mild to moderate essential hypertension. Patients in group 1 had uncontrolled BP (sitting diastolic BP [DBP] ≥90 mm Hg

2014 Current therapeutic research, clinical and experimental Controlled trial quality: uncertain PubMed abstract

16. [Reduced progression, increased mortality in chronic renal disease after treatment with the angiotensin-converting enzyme inhibitor benazepril]. (Abstract)

[Reduced progression, increased mortality in chronic renal disease after treatment with the angiotensin-converting enzyme inhibitor benazepril]. 8928272 1996 11 13 2012 11 15 0041-5782 158 41 1996 Oct 07 Ugeskrift for laeger Ugeskr. Laeg. [Reduced progression, increased mortality in chronic renal disease after treatment with the angiotensin-converting enzyme inhibitor benazepril]. 5798-9 Pedersen E B EB Arhus Universitetshospital, Forskningslaboratoriet for Nyresygdomme og Blodtryksforhøjelse (...) . dan Clinical Trial Journal Article Multicenter Study Randomized Controlled Trial Nedsat progressionshastighed ved kronisk nyresygdom efter behandling med den angiotensinkonverterende enzymhaemmer benazepril, men også øget mortalitet. Denmark Ugeskr Laeger 0141730 0041-5782 0 Angiotensin-Converting Enzyme Inhibitors 0 Antihypertensive Agents 0 Benzazepines UDM7Q7QWP8 benazepril IM Angiotensin-Converting Enzyme Inhibitors therapeutic use Antihypertensive Agents therapeutic use Benzazepines

1996 Ugeskrift for laeger Controlled trial quality: uncertain

17. Benazepril increases feed intake and body weight in healthy growing cats. (Abstract)

Benazepril increases feed intake and body weight in healthy growing cats. 16669867 2006 06 20 2012 11 15 0140-7783 29 3 2006 Jun Journal of veterinary pharmacology and therapeutics J. Vet. Pharmacol. Ther. Benazepril increases feed intake and body weight in healthy growing cats. 225-7 King J N JN Novartis Animal Health Inc., Basel, Switzerland. jonathan.king@novartis.com Seewald W W King S S Goldenthal E E eng Journal Article Randomized Controlled Trial England J Vet Pharmacol Ther 7910920 0140 (...) -7783 0 Angiotensin-Converting Enzyme Inhibitors 0 Benzazepines UDM7Q7QWP8 benazepril IM Administration, Oral Angiotensin-Converting Enzyme Inhibitors administration & dosage pharmacology Animals Benzazepines administration & dosage pharmacology Body Weight drug effects Cats growth & development metabolism Eating drug effects Female Male 2006 5 4 9 0 2006 6 21 9 0 2006 5 4 9 0 ppublish 16669867 JVP736 10.1111/j.1365-2885.2006.00736.x

2006 Journal of veterinary pharmacology and therapeutics Controlled trial quality: uncertain

18. A comparison in young and elderly subjects of the pharmacokinetics and pharmacodynamics of single and multiple doses of benazepril. (Full text)

A comparison in young and elderly subjects of the pharmacokinetics and pharmacodynamics of single and multiple doses of benazepril. 1. The pharmacokinetics and pharmacodynamics of single and multiple oral doses of the ACE inhibitor benazepril were investigated in young and elderly normotensive subjects. 2. Following multiple doses the trough concentrations were significantly higher in the elderly and the areas under the plasma concentration-time curves (AUC0-24) were significantly greater (...) , by approximately 23%. 3. The fall in blood pressure tended to be greater in the elderly subjects but this is likely to be attributable to their higher initial blood pressures, although it may reflect the small differences in pharmacokinetics. 4. The age related differences in kinetics and dynamics following multiple dosing are quantitatively similar to those obtained with single doses. However, there appears to be a quantitative difference between benazepril and other ACE inhibitors in that the age related

1993 British journal of clinical pharmacology PubMed abstract

19. Amlodipine+Benazepril is Superior to Hydrochlorothiazide+Benazepril Irrespective of Baseline Pulse Pressure: Subanalysis of the ACCOMPLISH Trial. (Full text)

Amlodipine+Benazepril is Superior to Hydrochlorothiazide+Benazepril Irrespective of Baseline Pulse Pressure: Subanalysis of the ACCOMPLISH Trial. Pulse pressure (PP) is an independent risk factor for cardiovascular (CV) disease and death but few studies have investigated the effect of antihypertensive treatments in relation to PP levels before treatment. The Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial showed (...) that the combination of benazepril+amlodipine (B+A) is superior to benazepril+hydrochlorothiazide (B+H) in reducing CV events. We aimed to investigate whether the treatment effects in the ACCOMPLISH trial were dependent on baseline PP. High-risk hypertensive patients (n=11,499) were randomized to double-blinded treatment with single-pill combinations of either B+A or B+H and followed for 36 months. Patients were divided into tertiles according to their baseline PP and events (CV mortality/myocardial infarction

2015 Journal of clinical hypertension (Greenwich, Conn.) Controlled trial quality: predicted high PubMed abstract

20. Comparison of benazepril and losartan on endothelial function and vascular stiffness in patients with Type 2 diabetes mellitus and hypertension: A randomized controlled trial. (Full text)

Comparison of benazepril and losartan on endothelial function and vascular stiffness in patients with Type 2 diabetes mellitus and hypertension: A randomized controlled trial. The purpose of this study was to compare the effects of benazepril and losartan on endothelial function and vascular stiffness, in patients with diabetes mellitus and hypertension.We included hypertensive diabetic patients with an office systolic blood pressure (BP) ⩾ 130 mmHg and/or diastolic BP ⩾ 80 mmHg. Patients were (...) rolled over to amlodipine for 6 weeks, then we performed C-reactive protein assays, BP measurement and vascular tests; next, patients were randomized to benazepril or losartan. The tests were repeated after 12 weeks.We randomized 14 patients to benazepril and 16 to losartan. There were no differences in systolic (139 versus 134 mmHg, p = 0.618) and diastolic (82 versus 80 mmHg, p = 0.950) BP at the end of the study. C-reactive protein values were lower in the benazepril group (0.38 versus 0.42 mg/dl

2015 Journal of the renin-angiotensin-aldosterone system : JRAAS Controlled trial quality: uncertain PubMed abstract